YiChang HEC ChangJiang Pharmaceutical Full Year 2024 Earnings: EPS: CN¥0.55 (vs CN¥2.26 in FY 2023)

YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥3.72b (down 41% from FY 2023).
• Net income: CN¥482.7m (down 76% from FY 2023).
• Profit margin: 13% (down from 32% in FY 2023). The decrease in margin was driven by lower revenue.
• EPS: CN¥0.55 (down from CN¥2.26 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

YiChang HEC ChangJiang Pharmaceutical Earnings Insights

Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 9.2% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's shares are down 3.9% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 1 warning sign for YiChang HEC ChangJiang Pharmaceutical that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.